Evercore Upgrades Intellia After New Hypothesis Explains Nex-z Liver Safety Signal
Intellia stock upgraded after solving liver risk issue; trials resume, new safety steps added, and another drug shows strong results.
/ 10 items
#NTLA↓
Cash Constraints Force Wolfe to Downgrade Intellia to Underperform
Concerns over limited cash runway and slower clinical progress weigh on the stock.
Analysts Reiterate Buy Ratings on Intellia as lonvo-z Shows Deeper Benefits in HAELO Trial
Intellia’s one-time gene therapy cut HAE attacks ~90%, boosting hopes for a lasting treatment; FDA review underway, launch possible in 2027.
FDA Lifts Hold on Intellia’s Phase 3 Gene-Editing Trial for Deadly Heart Disease
Intellia Therapeutics gets FDA approval to resume its Phase 3 trial for nexiguran ziclumeran, a gene-editing treatment for ATTR-CM heart disease, boosting shares by 6%.
Intellia Shares Jump After FDA Lifts Clinical Hold on Gene Therapy Trial
Intellia Therapeutics’ stock rises as the FDA clears a Phase 3 trial for its gene therapy, nexiguran ziclumeran, for a rare genetic disease.
Intellia Therapeutics Shares Plunge 29% After FDA Pauses Key Gene Therapy Trials
Intellia Therapeutics (NTLA) shares fell 29% premarket after the FDA paused two late-stage gene-editing trials following a patient death linked to liver complications.